Literature DB >> 31896372

Comparison of surveillance and clinical cultures to measure the impact of infection control interventions on the incidence of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in the hospital.

Surbhi Leekha1, Lyndsay M O'Hara1, Alyssa Sbarra2, Shanshan Li3, Anthony D Harris1.   

Abstract

OBJECTIVE: To evaluate whether clinical cultures are an appropriate surrogate for surveillance cultures to measure the effect of interventions on the incidence of MRSA and VRE in the hospital.
DESIGN: Cross-sectional and quasi-experimental, retrospective analysis. SETTING AND POPULATION: Convenience sample of patients admitted between January 1, 2002, and June 31, 2011, to the medical intensive care unit (MICU) and surgical intensive care unit (SICU) of an acute-care hospital in the United States.
INTERVENTIONS: Asynchronously in the MICU and SICU, we introduced (1) universal glove and gown use, (2) bundled intervention to prevent central-line-associated bloodstream infection, and (3) daily chlorhexidine gluconate bathing.
RESULTS: We observed a statistically significant correlation between surveillance and clinical culture-based incidence rates of MRSA in the MICU (0.32; P < .001) and the SICU (0.37; P < .001) but not for VRE in either the MICU (0.16, P = .11) or the SICU (0.15; P = .12). For VRE, but not for MRSA, incidence density rates based on surveillance cultures were 2- to 4-fold higher than for clinical cultures. When evaluating the impacts of the interventions, different effect estimates were noted for universal glove and gown use on MRSA acquisition in MICU, and for VRE acquisition in both the MICU and the SICU based on surveillance versus clinical cultures.
CONCLUSIONS: For multidrug-resistant organism acquisition, surveillance cultures should be used when feasible because clinical cultures may not be an appropriate surrogate. Clinical or surveillance-based end points for infection control interventions should reflect the conceptual model from colonization to infection and where an intervention might have an effect, rather than considering them interchangeable.

Entities:  

Year:  2020        PMID: 31896372      PMCID: PMC7007838          DOI: 10.1017/ice.2019.322

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  22 in total

1.  The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable.

Authors:  M J Bonten; S Slaughter; A W Ambergen; M K Hayden; J van Voorhis; C Nathan; R A Weinstein
Journal:  Arch Intern Med       Date:  1998-05-25

2.  Discontinuing contact precautions for multidrug-resistant organisms: A systematic literature review and meta-analysis.

Authors:  Alexandre R Marra; Michael B Edmond; Marin L Schweizer; Grace W Ryan; Daniel J Diekema
Journal:  Am J Infect Control       Date:  2017-10-12       Impact factor: 2.918

3.  Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Susan S Huang; Deborah S Yokoe; Virginia L Hinrichsen; Laura S Spurchise; Rupak Datta; Irina Miroshnik; Richard Platt
Journal:  Clin Infect Dis       Date:  2006-09-14       Impact factor: 9.079

4.  Effect of daily chlorhexidine bathing on hospital-acquired infection.

Authors:  Michael W Climo; Deborah S Yokoe; David K Warren; Trish M Perl; Maureen Bolon; Loreen A Herwaldt; Robert A Weinstein; Kent A Sepkowitz; John A Jernigan; Kakotan Sanogo; Edward S Wong
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

5.  Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial.

Authors:  Anthony D Harris; Lisa Pineles; Beverly Belton; J Kristie Johnson; Michelle Shardell; Mark Loeb; Robin Newhouse; Louise Dembry; Barbara Braun; Eli N Perencevich; Kendall K Hall; Daniel J Morgan; Syed K Shahryar; Connie S Price; Joseph J Gadbaw; Marci Drees; Daniel H Kett; L Silvia Muñoz-Price; Jesse T Jacob; Loreen A Herwaldt; Carol A Sulis; Deborah S Yokoe; Lisa Maragakis; Matthew E Lissauer; Marcus J Zervos; David K Warren; Robin L Carver; Deverick J Anderson; David P Calfee; Jason E Bowling; Nasia Safdar
Journal:  JAMA       Date:  2013-10-16       Impact factor: 56.272

Review 6.  Prevention and control of methicillin-resistant Staphylococcus aureus infections.

Authors:  Barry M Farr
Journal:  Curr Opin Infect Dis       Date:  2004-08       Impact factor: 4.915

7.  Control of endemic vancomycin-resistant Enterococcus among inpatients at a university hospital.

Authors:  David P Calfee; Eve T Giannetta; Lisa J Durbin; Teresa P Germanson; Barry M Farr
Journal:  Clin Infect Dis       Date:  2003-07-14       Impact factor: 9.079

8.  The clinical significance of carbapenem-resistant Klebsiella pneumoniae rectal colonization in critically ill patients: from colonization to bloodstream infection.

Authors:  Konstantina Kontopoulou; Elias Iosifidis; Eleni Antoniadou; Polychronis Tasioudis; Efthymia Petinaki; Ergina Malli; Symeon Metallidis; Alkiviadis Vatopoulos; Nicolaos Malisiovas
Journal:  J Med Microbiol       Date:  2019-01-30       Impact factor: 2.472

9.  Impact of Discontinuing Contact Precautions for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus: An Interrupted Time Series Analysis.

Authors:  Gonzalo Bearman; Salma Abbas; Nadia Masroor; Kakotan Sanogo; Ginger Vanhoozer; Kaila Cooper; Michelle Doll; Michael P Stevens; Michael B Edmond
Journal:  Infect Control Hosp Epidemiol       Date:  2018-03-27       Impact factor: 3.254

10.  Factors associated with bacteraemia due to multidrug-resistant organisms among bacteraemic patients with multidrug-resistant organism carriage: a case control study.

Authors:  Hélène Mascitti; Clara Duran; Elisabeth-Marie Nemo; Frédérique Bouchand; Ruxandra Câlin; Alexis Descatha; Jean-Louis Gaillard; Christine Lawrence; Benjamin Davido; François Barbier; Aurélien Dinh
Journal:  Antimicrob Resist Infect Control       Date:  2018-09-29       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.